Omega Funds has raised $647 million for the investment shop’s latest round aimed at life sciences companies targeting unmet ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...

With its Poolbeg Pharma merger plans having bitten the dust and key assets sold off to Gilead, Hookipa Pharma has decided ...

Berkeley is getting a boost, launching a dedicated space for expanding companies that have outgrown their starter homes. | A biotech incubator at the University of California, Berkeley is getting a ...

The PD-1xVEGF dealmaking wave that has captivated Western pharma companies is now surging within China. | Sino Biopharm said ...

On an investor call Friday, analysts grilled the company over its apparent lack of transparency on the matter.

Kennedy Jr. has downplayed the effectiveness of the long-used vaccine and instead promoted the development of new treatments ...

Sail Biomedicines is shrinking its crew for the second time this year. | Sail Biomedicines is shrinking its crew for the ...

Heartflow is once again looking for a path to go public, with a filing for a Nasdaq IPO. | The former Fierce Medtech Fierce ...

To secure the antibody, I-Mab is paying $1.8 million upfront to buy Bridge Health, to be followed by noncontingent quarterly ...

With GSK kicking its research and development engine into high gear in recent years, a shuffling of the scientific priorities ...

The U.K. is establishing a new biosecurity center designed to improve research into potentially pandemic-causing pathogens ...